Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14662248 | 0.91 | CYP11B2 (0.42) | CYP11B2SCD5ACACBUSP30USP2 | |
| SCHEMBL904136 | 0.90 | USP2 (0.49) | CYP11B2SCD5ACACBGPR183USP2 | |
| SCHEMBL16835515 | 0.90 | CYP11B2 (0.46) | CYP11B2SCD5ACACBHDAC2GPR183 | |
| SCHEMBL25336751 | 0.87 | CYP11B2 (0.45) | CYP11B2SCD5ACACBHDAC2GPR183 | |
| SCHEMBL6114857 | 0.87 | USP2 (0.43) | CYP11B2SCD5ACACBGPR183USP2 | |
| SCHEMBL16835469 | 0.86 | CYP11B2 (0.51) | CYP11B2SCD5ACACBHDAC2GPR183 | |
| SCHEMBL20234376 | 0.86 | CYP11B2 (0.48) | CYP11B2SCD5ACACBHDAC2GPR183 | |
| SCHEMBL21285082 | 0.86 | USP2 (0.47) | CYP11B2SCD5ACACBGPR183USP2 | |
| SCHEMBL19273133 | 0.85 | CYP11B2 (0.38) | CYP11B2SCD5ACACBHDAC2GPR183 | |
| SCHEMBL6868004 | 0.85 | CYP11B2 (0.54) | CYP11B2SCD5ACACBHDAC2GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4413985-B1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-05-06 | — | — | EP | disclosed |
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4663190-A2 | MUSCARINIC RECEPTOR AGONISTS | Nxera Pharma UK Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| EP-4647431-A1 | COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Gan & lee Pharm Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340531-A1 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | NXERA PHARMA UK LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4630422-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4508045-B1 | CITRATE SALT FORMS OF A MUSCARINIC RECEPTOR AGONIST | NXERA PHARMA UK LTD (GB) | 2025-10-01 | — | — | EP | disclosed |
| US-12398119-B2 | Piperazine azaspiro derivatives | PFIZER INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4587424-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | Bridgene Biosciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2014152114-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275014-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275014-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| WO-2014045031-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-03-27 | — | — | WO | disclosed |
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20130211087-A1 | 7-AZA-SPIRO[3,5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-08-15 | — | — | US | disclosed |
| US-8394787-B2 | 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20120129830-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275014-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | CYP11B2 543/4885SCD5 4109/4885ACACB 1326/4885 |
| US-12398119-B2 | Piperazine azaspiro derivatives | CHRM1, CHRM2, CHRM5 | CYP11B2 472/4885SCD5 3472/4885ACACB 4682/4885 |
| US-20140045813-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | CYP11B2 589/4885SCD5 4238/4885ACACB 2355/4885 |
| US-20130211087-A1 | 7-AZA-SPIRO[3,5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FAAH, FAAH2, ASAH1 | CYP11B2 784/4885SCD5 28/4885ACACB 283/4885 |
| US-20120129830-A1 | 7-AZA-SPIRO[3.5]NONANE-7-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | HDAC7, NR3C2, EPOR | CYP11B2 102/4885SCD5 3594/4885ACACB 4108/4885 |
| US-20110319381-A1 | DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT9, IDH3B, DHFR | CYP11B2 332/4885SCD5 2039/4885ACACB 2951/4885 |
| US-20250340531-A1 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | CHRM3, CHRM2, CHRM4 | CYP11B2 364/4885SCD5 3358/4885ACACB 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.